Allergen immunotherapy (AIT) still remains the only disease- modifying treatment for immunoglobulin E (IgE)-mediated allergies with proven sustained efficacy upon discontinuation of the treatment, provided it is administered regularly for at least 3 years. Aluminum salts still remain a common depot and adjuvant for subcutaneous AIT that moderately reduce allergenicity; however, the risk of severe allergic reactions persists, making careful updosing protocols necessary. These characteristics justify the need for shorter treatments with improved safety profiles.
